Inhibition of DNA Methylation and Histone Deacetylation Prevents Murine Lung Cancer

Cancer Research

Volumn 63, Issue 21, 2003, Pages 7089-7093

  Belinsky, Steven A ^a   Klinge, Donna M ^a   Stidley, Christine A ^b   Issa, Jean Pierre ^c   Herman, James G ^d   March, Thomas H ^a   Baylin, Stephen B ^d  

^a LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF NEW MEXICO   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BUTYRIC ACID DERIVATIVE; CYTOSINE DNA METHYLTRANSFERASE 1; DNA METHYLTRANSFERASE; HISTONE DEACETYLASE INHIBITOR; SODIUM PHENYLBUTYRATE; UNCLASSIFIED DRUG;

ALLELE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CANCER PREVENTION; CANCER RISK; CAUSE OF DEATH; CONTROLLED STUDY; DEACETYLATION; DEMETHYLATION; DNA METHYLATION; DNA METHYLATION INHIBITION; DNMT1 GENE; DOSE RESPONSE; FEMALE; GENE; GENE DISRUPTION; GENE MUTATION; GENE SILENCING; GERM LINE; INHIBITION KINETICS; LUNG ALVEOLUS CELL TYPE 2; LUNG CANCER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; REPRODUCIBILITY; STATISTICAL SIGNIFICANCE; TOBACCO; TRANSCRIPTION REGULATION; TUMOR SUPPRESSOR GENE; UNITED STATES; WILD TYPE;

ALLELES; ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CYTOSINE; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DRUG SYNERGISM; ENZYME INHIBITORS; FEMALE; GENE DOSAGE; HISTONE DEACETYLASES; HISTONES; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED A; PHENYLBUTYRATES;

EID: 0242442588     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Greenlee, R. T., Hill-Harmon, M. B., Murray, T., and Thun, M. Cancer statistics 2001. CA Cancer J. Clin., 51: 15-36, 2001.
2. Schiller, J. H., Harrington, D., Belani, C. P., Langer, C., Sandler, A., Krook, J., Zhu, J., and Johnson, D. H. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N. Engl. J. Med., 346: 92-98, 2002.
3. Scagliotti, G. V., De Marinis, F., Rinaldi, M., Crino, L., Gridelli, C., Ricci, S., and Tonato, M. Phase III randomized trial comparing three platinum-based doublets in advanced non-small cell lung cancer. J. Clin. Oncol., 20: 4285-4291, 2002.
4. Baylin, S. B., and Herman, J. G. DNA hypermethylation in tumorigenesis: epigenetics joins genetics. Trends Genet., 16: 168-174. 2000.
5. Jones, P. A., and Laird, P. W. Cancer epigenetics comes of age. Nat. Genet., 21: 163-167, 1999.
6. Kelly, W. K., O'Connor, O. A., and Marks, P. A. Histone deacetylase inhibitors: from target to clinical trials. Exp. Opin. Investig. Drugs, 11: 1695-1713, 2002.
7. Jones, P. A., and Baylin, S. B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet., 3: 415-428, 2002.
8. Szyf, M., Kaplan, F., Mann, V., Giloh, H., Kedar, E., and Razin, A. Cell cycle-dependent regulation of eukaryotic DNA methylase level. J. Biol. Chem., 260: 8653-8656, 1985.
9. Robertson, K. D., Uzvolgyi, E., Liang, G., Talmadge, C., Sumegi, J., Gonzales, F. A., and Jones, P. A. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: Coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res., 27: 2291-2298, 1999.
10. Okano, M., Bell, D. W., Haber, D. A., and Li, E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell, 99: 247-257, 1999.
11. Roundtree, M. R., Bachman, K. E., and Baylin, S. B. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat. Genet., 25: 269-277, 2000.
12. Fuks, F., Burgers, W. A., Brehm, A., Hughes-Davies. L., and Kouzarides, T. DNA methyltransferase Dnmt1 associates with histone deacetylase activity. Nat. Gen., 24: 88-91, 2000.
13. Santi, D. V., Garrett, C. E., and Barr, P. J. On the mechanism of inhibition of DNA-cytosine methyltransferase by cytidine analogs. Cell, 83: 9-10, 1983.
14. Cameron, E. E., Bachman, K. E., Myohanen, S., Herman, J. G., and Baylin, S. B. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat. Gen., 21: 103-107, 1999.
15. Laird, P. W., Jackson-Grusby, L., Fazeli, A., Dickinson, S. L., Jung, W. E., Li, E., Weinberg, R. A., and Jaenisch, R. Suppression of intestinal neoplasia by DNA hypomethylation. Cell, 81: 197-205, 1995.
16. Belinsky, S. A., Nikula, K. J., Baylin, S. B., and Issa, J-P. Increased cytosine DNA-methyltransferase activity is target-cell-specific and an early event in lung cancer. Proc. Natl. Acad. Sci. USA, 93: 4045-4050, 1996.
17. Lantry, L. E., Zhang, Z., Crist, K. A., Wang, Y., Kelloff, G. J., Lubet, R. A., and You, M. 5-Aza-2′-deoxycytidine is chemopreventive in a 4-(methyl-nitrosamino)-1-(3-pyridyl)-1-butanone-induced primary mouse lung tumor model. Carcinogenesis (Lond.), 20: 343-346. 1999.
18. Eads, C. A., Nickel, A. E., and Laird, P. W. Complete genetic suppression of polyp formation and reduction of CpG-island hypermethylation in Apc(Min/+) DNMT1-hypomorphic mice. Cancer Res., 62: 1296-1299, 2002.
19. Belinsky, S. A., Devereux, T. R., Foley, J. F., Maronpot, R. R., and Anderson, M. W. Role of the alveolar type II cell in the development and progression of pulmonary tumors induced by 4-(methylinitrosamino)-1-(3-pyridyl)-1-butanone in the A/J mouse. Cancer Res., 52: 3164-3173, 1992.
20. Malkinson, A. M. The genetic basis of susceptibility to lung tumors in mice. Toxicology, 54: 349-362, 1989.
21. Malkinson, A. M., Nesbitt, M. N., and Skamene, E. Susceptibility to urethan-induced pulmonary adenomas between A/J and C57BL/6J mice: Use of AxB and BxA recombinant inbred lines indicating a three-locus genetic model. J. Natl. Cancer Inst., 75: 971-974, 1985.
22. You, M., Wang, Y., Stoner, G., You, L., Maronpot, R., Reynolds, S. H., and Anderson, M. Parental bias of Ki-ras oncogenes detected in lung tumors from mouse hybrids. Proc. Natl. Acad. Sci. USA, 89: 5804-5808, 1992.
23. Rhee, I., Bachman, K. E., Park, B. H., Jair, K. W., Yen, R. W. C., Schuebel, K. E., Cul, H., Feinberg, A. P., Lengauer, C., Kinzler, K. W., Baylin, S. B., and Vogelstein, B. DNMT1 and DNMT3b cooperate to silence genes in human cancer cells. Nature (Lond.), 416: 552-556, 2002.
24. Festing, M. F., Lin, L., Devereux, T. R., Gao, F., Yang, A., Anna, C. H., White, C. M., Malkinson. A. M., and You, M. At least four gene loci and gender are associated with susceptibility to the chemical induction of lung adenomas in A/J X BALB/c mice. Genomics 15: 129-136, 1998.
25. Risch, H. A., Howe, G. R., Jain, M., Burch, J. D., Holoway, E. J., and Miller, A. B. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am. J. Epidemiol., 138: 281-293, 1993.
26. Zang, E. A., and Wynder, E. L. Differences in lung cancer risk between men and women: examination of the evidence. J. Natl. Cancer Inst., 88: 183-192, 1996.
27. Bestor, T. H. Activation of mammalian DNA-methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J., 11: 2611-2617, 1992.
28. Bachman, K. E., Rountree, M. R., and Baylin, S. B. Dnmt3a and Dnmt3b are transcriptional repressors that exhibit unique localization properties to heterchromatin. J. Biol. Chem., 276: 32282-32287, 2001.
29. Wu, J., Issa, J-P., Herman, J., Bassett, D. E., Jr., Nelkin, B. D., and Baylin, S. B. Expression of an exogenous eukaryotic DNA methyltransferase gene induces transformation of NIH 3T3 cells. Proc. Natl. Acad. Sci. USA, 90: 8891-8895, 1993.
30. Kim, G. D., Ni, J., Kelesogiu, N., Roberts, R. J., and Pradhan, S. Co-operation and communication between the human maintenance and de novo DNA (cytosine-5) methyltransferases. EMBO J., 21: 4183-4195, 2002.
31. Wijermans, P. Lubbet, M. Verhoef, G. Bosly, A. Ravoet, C., and Andre, M. Low dose 5-aza-2′-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndromes: a multicenter phase II study in elderly patients. J. Clin. Oncol., 18: 956-962, 2000.
32. Johnstone, R. W. (2002) Histone-deacetylase inhibitors: novel drugs for the treatment of cancer. Nat. Rev., 1: 287-299, 2002.
33. Gaudet, F., Hodgson, J. G., Eden, A., Jackson-Grusby, L., Dausman, J., Gray, J. W., Leonhardt, H., and Jaenisch, R. Induction of tumors in mice by genomic hypomethylation. Science (Wash. DC), 300: 489-492, 2002.
34. Cheng, J. C., Matsen, C. B., Gonzales, F. A., Ye, W., Greer, S. Marquez, V. E., Jones, P. A., and Selker, E. U. Inhibition of DNA methylation and reactivation of silenced genes by zebularine. J. Natl. Cancer Inst., 95: 399-409, 2003.
35. Clark, L. C., Combs, G. F., Tumbull, B. W., Slate, E. H., Chalker, D. K., Chow, J., and Taylor, J. R. Effects of selenium supplementation for cancer prevention in patients with carcinoma of the skin. JAMA, 276: 1957-1963, 1996.
36. Fiala, E. S., Staretz, M. E., Pandya, G. A., El-Bayoumy, K., and Hamilton, S. R. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis (Lond.), 19: 597-604, 1998.